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Osteoarthritis (OA) is a disease of the whole joint organ, characterized by the loss of cartilage, and structural changes in bone
including the formation of osteophytes, causing disability and loss of function. It is also associated with systemic mediators and
low-grade inflammation. Currently, there is negligible/no availability of specific biomarkers that can be used to facilitate the
diagnosis and treatment of OA. The most unmet clinical need is, however, related to the monitoring of disease progression over
a short period that can be used in clinical trials. In this review, the value of biomarkers identified over the past decade has been
highlighted. These biomarkers are associated with the synthesis and breakdown of cartilage, including collagenous and
noncollagenous biomarkers, inflammatory and anti-inflammatory biomarkers, expressed in the biological fluid such as serum,
synovial fluid, and urine. Broad validation of novel and clinically applicable biomarkers and their involvement in the pathways
are particularly needed for early-stage diagnosis, monitoring disease progression, and severity and examining new drugs to
mitigate the effects of this highly prevalent and debilitating condition.
1. Introduction
Osteoarthritis (OA) is a group of pathologies involving joints
deformities, degeneration of articular cartilage, subchondral
sclerosis, osteophytes formation, and joint structural deterio-
ration that causes disability and joint pain [1]. In 2016, Oste-
oarthritis Research Society International (OARSI) submitted
a white paper supporting the argument that OA is a serious
disease because it affects the quality of life associated with
increased risk of mortality and affects an economical burden
to society [2]. With an estimated 303 million people affected
worldwide, most people over the age of 60 have evidence of
OA but it is estimated that 80% of the population has radio-
graphic evidence, and symptomatic OA occurs in only 25%
of people. According to the Global Burden of Disease
(GBD) 2017 studies, the prevalence of knee OA is positively
correlated with increased age, and radiographic knee OA is
more prevalent compared to systematic knee OA [3]. The
population-based studies have shown that the global preva-
lence of knee OA was 16.0% in individuals over 15 years of
age and 22.9% in individuals over 40 years of age [4]. Accord-
ing to a National Health Interview Survey, approximately 14
million people are affected by systematic knee OA in the
United States [5]. The prevalence rate of OA in India was
found to be around 22% to 36%, and the prevalence of OA
in the female gender is 31.6%, with the associate factors for
OA that are obesity (p = 0:04), age (p = 0:001), and sedentary
work (p = 0:0001) [6]. Epidemiologic studies have
highlighted responsible risk factors, systemic factors (obesity,
gender, genetic predisposition, etc.), and joint-related risk
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factors (joint injuries, joint misalignment) associated with
OA development and progress [7]. OA is usually diagnosed
by clinical manifestations (pain, swelling, morning stiffness
for <30 minutes), X-rays, and magnetic resonance imaging
(MRI). More recent advances in understanding OA have
stemmed from epidemiologic studies using MRI, highlight-
ing a very high frequency of pathology of cartilage, menisci,
subchondral bone, and synovium [8]. Importantly, these
studies have established the relevance of these tissues to joint
pain associations, with pathology ranging from minor tissue
lesions to severe total joint deviations. MRI provides addi-
tional information in the complex condition but is not used
in the early-stage detection of OA. However, it is not avail-
able routinely and is usually restricted to clinical trials, where
highly sensitive measures are needed to assess changes [9].
OA is a multifactorial disease where affected tissues
undergo metabolic, structural, biochemical, and functional
changes [10]. It is a result of the failure of chondrocytes to
maintain homeostasis between synthesis and breakdown of
the extracellular component such as proteoglycans and colla-
gens, leading to inflammation of the synovium and joint cap-
sule [11]. It is still unclear that which factors and processes
initiate an imbalance between synthesis and breakdown of
these components. These cartilage breakdown products are
released into the synovial space, and the identity (type II col-
lagen marker, COMP, etc)) of these products has been inves-
tigated as a potential biomarker for OA development [12].
2. The Clinical Need for Biomarkers in OA
The development of early OA interventions that could truly
change the natural progression of OA is hampered by the
lack of means to recognize early OA. It is being such a
slow-progressing disease, and pathology is usually well estab-
lished before symptoms are detected. There are no/negligible
disease-modifying OA treatments to limit structural deterio-
ration or clinical improvements in the disease, although
recent advances may provide a real change in the future
[13]. Also, another major clinical need is to identify bio-
markers as shown in Figure 1 that may allow for monitoring
disease progression in a shorter period, allowing for a more
feasible clinical trial. To understand OA pathology involving
molecular mechanisms, there is a need for specific molecules
and pathways for early-stage detection and progression of
OA. The breakdown products of cartilage and various cyto-
kines that increase/decrease in the inflammation site as well
as in circulating blood have been identified to be used as bio-
markers for understating OA pathology [14], but the exact
mechanism is still unknown. The discovery of new therapeu-
tic drugs requires knowledge about the molecules and the
associated pathways to understand the specific target bond.
These biomarker molecules and related signaling pathways
play role in regulating the maintenance of mature chondro-
cytes and turnover of articular cartilage, synovial inflamma-
tion, etc. [15].
Figure 1: Biomarkers in drug discovery and development by using the proteomic approach.
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3. Biomarker Candidates in OA
In 2001, the Biomarkers Definitions Working Group
(BDWG) defined the biomarker as a “characteristic that is
objectively measured and evaluated as an indicator of normal
biological processes or pharmacological responses to a thera-
peutic intervention” [16]. The biomarker for OA should
reflect dynamic and quantitative changes in joint tissues.
There is accumulating evidence that these biomarkers can
not only distinguish the cartilage breakdown changes in the
cartilage of knee OA but can also diagnose functional, struc-
tural, and biochemical changes and associated damage in the
bone and the subchondral tissue [17]. Several biomarkers
have been proposed in OA over the years, for early-stage
diagnosis, monitoring disease progression or severity, and
for examining drug potential’s efficacy. The identified bio-
markers should be compatible with pain score, clinical, and
radiological findings of disease, and the smallest changes in
concentration of biomarkers should be related to disease
severity and pathology [18]. To understand the role of bio-
markers in clinical trials, it is necessary to standardize mea-
surement methods such as sample collection time, sample
storage status, physical activity, age, sex, disease progression,
and information about medications which is used for the
treatment of the patient [19]. For the discovery of drug devel-
opment methods and meaningful use of biomarker in clinical
trial and availability in the public, a guideline was issued by
the Food and Drug Administration (FDA) that involved a
pathway for identifying a biomarker with clinical outcome
including in vitro and in vivo studies from an optimal dose
of therapeutics, monitoring therapeutic responses, side
effects, clinical validity (clear difference in both group), and
clinical utility (effect on health) [20]. These biomarkers
include proteins, metabolites, carbohydrate biomarkers,
genomic biomarkers, cellular biomarkers, and imaging bio-
markers and are usually measured in a selected body fluid
such as blood, serum, urine, synovial fluid, and cartilage tis-
sue. These markers are reflected in bone loss, chondrocytes
erosion, and inflammation of joint tissue as shown in
Figure 2 [21]. Several biochemical markers are usually the
Figure 2: Physiological, molecular, and metabolic alterations are responsible for the cause of osteoarthritis. CPII: type II collagen propeptide;
C2C: neoepitope of type II collagen; Coll 2-1: 9-amino acid peptide of type II collagen (nitrated form Coll 2-1 NO2); CTX: C-terminal
telopeptide of collagen; PIIANP: N-propeptide IIA of type II collagen; PIICP: C-propeptide of collagen type II; COMP: cartilage
oligomeric matrix protein; FSTL-1: follistatin-like protein 1; CRP: C-reactive protein; IL: interleukin; TNF: tumor necrosis factor; YKL-40:
chitinase-3-like protein 1; ADMTs: A Disintegrin and Metalloproteinase with Thrombospondin motifs; MMP: matrix metalloproteinase;
PTMs: posttranslational modifications; D-COMP: deaminated epitope of cartilage oligomeric matrix protein; NF-κB: nuclear factor kappa
light chain enhancer of activated B cells; RANKL: receptor activator of NF-κB ligand; IFN-γ: interferon gamma; TLR4: toll-like receptor 4;
MAPK: mitogen-activated protein kinase.
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byproduct of cartilage breakdown, bone metabolism, lipid
metabolism, and the component of extracellular matrix mol-
ecules which are released into the blood or body fluids during
the process of tissue turnover. For this reason, different com-
binations of markers were reported to play an important role
in the prognosis of the disease [22]. However, very few bio-
markers (type II procollagen carboxy type 2-propeptide
(CPII), N-propeptide type IIA collagen (PIIANP), collagen
(uCTX-II), COLL2-1, and its nitrate form COLL2-1NO2
Fibulin-3 epitope, cartilage oligomeric matrix protein
(COMP), pentosidine and adipokines, etc.) have been identi-
fied for prediction of the development of OA [23]. For easy
access to these biomarkers, we have divided these biomarkers
based on their tissue origin and metabolism and discussed
each of these categories further as shown in Table 1. These
are (a) collagenous biomarkers, (b) noncollagenous bio-
markers, (c) inflammatory markers, (d) posttranslation mod-
ification biomarkers (e), and other biomarkers such as
adipokines [23]. Based on previous studies and reports, we
focused on how these biomarkers play role in OA progres-
sion and development involving multiple pathways, such as
wnt signaling, NF-κB pathway, and TLR-pathway [24].
3.1. Collagenous Biomarkers. Collagens are a large family of
proteins found in the various types of connective tissues such
as cartilage, bones, tendons, and muscles. During OA, break-
down and synthesis products of collagens have been evalu-
ated as biomarkers (type2 collagen, nitrate form of Coll-2,
procollagen–IIA, and urinary c-terminal crosslinking telo-
peptide (uCTX-II)) for the prediction of the development
and progression of OA [25].
Type II collagen (Coll-II) is the major collagen of the car-
tilage, and its cleavage products (Coll2-1 and Coll2-1NO2)
were upregulated by ~2-fold in the early stage of OA and
were decreased in severe cases [26]. Coll2-1 is a peptide mol-
ecule released from type-II collagen during cartilage erosion
and is a native form while Coll2-1NO2 is the nitrate form
of Coll2-1. Peptide nitration is formed by the reaction of aro-
matic amino acid with peroxynitrite (ONOO-); peroxynitrite
is a strong oxidant formed by the reaction of nitric oxide
(NO) and superoxide (O2
-). Both NO and (O2
-) are formed
in OA from macrophage cells and chondrocytes. Tyrosine,
located in the alpha chain of type-II collagen, bind with
nitrate, and form Coll2-1NO2 [27]. The nitrated form of Coll
2-1 reflects the oxidative-related cartilage degradation and
inflammation in OA. The concentration of Coll2-1 in the
serum remains constant throughout life but Coll2-1 and
Coll2-1NO2 levels were elevated in the serum and synovial
fluid (SF) of OA patients and lead cartilage degradation by
increase oxidative stress in disease conditions. Coll2-1NO2
can be a useful tool to identify oxidative-related cartilage deg-
radation, hence used for monitoring the effect of anti-
inflammatory and antioxidant drugs on the cartilage [28].
Destruction of collagen type II and related pathology phe-
nomenon is activated by the upregulation of WNT5A (wnt
signaling pathway) in OA-chondrocytes. In clinical studies,
it was found that silencing of WNT5A mRNA by small inter-
fering RNA (siRNA) prevents degradation of Coll-2 [29]. In
another study, treatment of OA by viscosupplementation
with hyaluronic acid, the Coll2-1 level was observed to be
reduced in the serum of OA, resulting in the prevention of
collagen destruction in OA, suggesting that Coll2-1 as a pre-
dictive marker for diagnosis of OA [30].
Procollagen-IIA is an N-terminal propeptide, cleaved by
procollagen-N and procollagen-C proteinases, producing
procollagen type-N-propeptide (PIIANP) and procollagen-
type-C propeptide (PIICP) [31]. PIIANP levels were down-
regulated in serum and OASF compared to healthy control.
Lower PIIANP was associated with greater osteophytes and
joint space contraction values, indicating that systemic
PIIANP does not reflect the local collagen tissue in knee
OA, but rather there is a more global cartilage anabolic reac-
tion. Proanabolic agents PIIANP may be suitable for treat-
ment therapy to prevent severe large joint OA [32].
Two more byproducts of collagen breakdown have been
identified, which are responsible for cartilage deformity, type
II procollagen carboxy-propeptide (CPII), and urinary c-
terminal crosslinking telopeptide [33]. CPII levels were
upregulated in serum and SF in the early stage of OA, while
the levels of CPII were found to be downregulated due to
chondrocyte failure and cartilage erosion [34]. The levels of
CPII were found to be directly associated with body mass
Table 1: The selected biomarkers of OA are classified according tissue involvement and metabolism.
Categories Candidate biomarkers with reference
Cartilage degradation biomarkers C2C [34], Coll2, Coll2-1, CoLL2-1NO [27], CTX-II [36], COMP [41], YKL-40 [65]
Cartilage synthesis biomarkers uCTX [36], PIIANP [31], PIIACP [32]
Synovial degradation biomarkers HA [48], fibuline-3 [53], follistatin-like protein 1(FSTL1) [56]
Synovial synthesis biomarkers sPIIINP [31]
Extracellular matrix biomarkers ARGS [50], MMPs [98]
Inflammatory biomarkers
Complement components [63],
cytokines (IL-1β, TNF-α, IL-4, IL-7, IL-8, IL-10) [68–73], and chemokines [75]
Posttranslation modification biomarkers DCOMP [81], pentosidine [83]
Other biomarkers ADMTS [88], obesity-related protein, and adipokines [94]
CTXII: type II collagen; C2C: type II collagen cleavage product; Coll 2: type II collagen, NO: nitrogen oxide; COMP: cartilage oligomeric matrix protein; YKL-
40: chitinase 3-like protein 1; PIIANP: type IIA collagen N-propeptide; PIICP: type II C propeptide; μCTX-1: urinary c-terminal crosslinking telopeptide II
collagen; HA: hyaluronic acid; sPIIINP: serum III procollagen; FIB3-1: fibulin-3 peptides; ARGS: aggrecanase-cleaved aggrecan; MMPs: matrix
metalloproteinases; IL-1β: interleukin 1 beta; TNF-α: tumour narcosis factor-alpha.
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index (BMI) and obesity. The underlying cause of the
increased level of CPII with an increment in the level of
BMI is not known, and the mechanism by which both are
correlated to each other in OA is still unclear [35]. Future
investigations regarding CPII involvement in OA may help
to understand the pathology and prognosis of OA.
Urinary c-terminal crosslinking telopeptide of type II col-
lagen (uCTX-II) is a catabolic product of type II collagen gen-
erated during articular cartilage degradation, excreted in SF
and urine, associated with cartilage degeneration of OA
[36]. Levels of uCTX-II are increased in the knee and hip
OA patients and generally increased with severity but not sig-
nificantly associated with radiographic knee pain. It is widely
accepted to reflect cartilage erosion. The elevated level of
uCTX-II is reported to predict the progression of joint space
narrowing in hip OA and is also correlated to bone marrow
abnormalities in disease conditions [37]. In a clinical trial, it
has been found that after hyaluronic acid injection, the
expression level of uCTX-II was decreased compared to base-
line. Based on proteomic and bioinformatic studies, uCTX-II
clusters with a biomarkers for bone metabolism [38]. It may
be one of the best potential biomarkers for OA in the diagno-
sis, severity, monitoring of disease progression, and drug
responses and is widely accepted to reflect cartilage erosion.
3.2. Noncollagenous Biomarkers. The extracellular matrix of
joints consists of collagens, noncollagenous proteins, water,
and lipids. Noncollagenous proteins include proteoglycans,
cartilage oligomeric matrix protein (COMP), hyaluronan,
aggrecan, fibulin, and glycoproteins such as follistatin-like
protein 1 (FSTIL-1). Noncollagenous proteins are synthe-
sized by osteoblasts and provide elasticity, strength, and flex-
ibility to the joints. During cartilage erosion, these proteins
get released into the SF that leads to OA. These proteins are
reported to play the role of biomarkers and may be useful
for the diagnosis and monitoring of OA progression [39].
Cartilage oligomeric matrix protein (COMP), also known
as thrombospondin-5, 524 kDa homopentameric, noncolla-
genous glycoproteins derived from the cartilage, is found in
ligaments and tendons and functions as a catalyst in collagen
fibril formation [39]. During injuries and early-stage OA,
COMP fragments get released into the joint which makes
COMP a marker for cartilage degradation. The expression
level of serum COMP was significantly elevated in the SF at
the early-stage OA but surprisingly level of COMP decreased
at the later stages of OA due to protease activity [40]. Also,
the COMP gene mRNA level in the peripheral blood sample
has been reported to be upregulated along with the COMP
protein level, in the OA patients, playing a role in the struc-
tural integrity of the cartilage through interaction with extra-
cellular matrix proteins by the cell surface integrin receptor
[41]. Another study confirmed that the expression of COMP
is reduced in the serum of late-stage OA due to proteolytic
activity in the affected cartilage as shown in Table 2 [42]. In
another study, COMP protein in OASF was downregulated
in early-stage OA compared to end-stage OA and showed a
positive linear correlation with age, but not significantly cor-
related with gender. The concentration of COMP protein in
the SF increased with the severity of OA and leads to cartilage
degradation [43]. Another study has found that COMP is
positively and significantly correlated with IL-1β but nega-
tively correlated with TNF-α in OA serum. The observation
was reconfirmed by another study stating that COMP levels
decreased with anti-IL-1α and IL-1β treatment and neutrali-
zation of IL-1α and IL-1β after the onset of disease and
reduced the joint inflammation and cartilage loss [44]. The
treatment of OA with mud-bath therapy (non-pharmacolog-
ical approach) had an effect on pain, visual analogue scale
(VAS) score, and Western Ontario and McMaster Universi-
ties Index (WOMAC) scores, but did not show any signifi-
cant impact on sCOMP and other serum biomarkers except
uCTX-II biomarker [45]. Increased COMP level in serum
along with clinical profile may help in diagnosing and man-
aging knee OA at the earliest possible stage.
Hyaluronan acid (HA) is the most important component
of SF, provides high viscosity and smoothness to the joints
and the resistance of cartilage to compression, and is associ-
ated with the radiographic progression of the disease [39].
The level of HA is significantly higher in the serum of OA,
but the level decreases in SF at the late-stage of OA. The
higher level of HA in serum is associated with the severity
of OA as measured by higher WOMAC scores and higher
Kellgrens and Lawrence (K&L) scores [46]. The K&L is a
method of classifying the severity of OA using the five grad-
ing score system; grade 0-no radiological finding of X-ray of
OA, grade 1-doubtful joint space narrowing (JSN) and osteo-
phytes lipping, grade 2-definite osteophytes and JSN, grade
3-moderate multiple osteophytes, sclerosis, and possible
deformity of bone ends, and grad 4-large osteophytes and
severe sclerosis definite deformity of bone ends [47]. In clin-
ical trials, injections of HA are used for the treatment of OA
that increases chondrocyte synthesis of endogenous HA,
prevents cartilage loss, promotes cartilage regeneration,
and inhibits joint stiffness by reducing the production of
proinflammatory mediators and metalloproteinases [48].
The hyaluronic acid injection is considered to be a safe pro-
cedure for the treatment of knee OA but has many side
effects such as a severe inflammatory reaction at the injec-
tion site and other risk factors including an allergic reaction.
Therefore, it is not commonly used but is used in severe con-
ditions for pain relief [49]. It can be concluded that HA
levels are associated with knee OA and play an important
role in the identification, elevation, management, and treat-
ment of knee OA patients.
Aggrecan: the second most important component of SF is
aggrecan, known as cartilage-specific proteoglycans core pro-
tein (cspcp) or chondroitin sulfate proteoglycan. It is the
major component of the extracellular matrix in cartilage
along with type II collagen and plays an important role in
mediating chondrocyte-chondrocyte and chondrocyte-ECM
interactions in the cartilage. In OA, it is a hallmark protein
for cartilage destruction [50]. In the cartilage, aggrecan is
cleaved by proteolytic enzymes such as matrix metallopro-
teinases (MMP1) and aggrecanases, and the expression level
of aggrecan gets decreased which causes cartilage destruc-
tions in OA. During in vivo studies, it has been found that
aggrecan levels were high in the early stage of OA to prevent
cartilage loss, but after some time, aggrecan levels get
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decreased due to proteolytic activity, leading to cartilage
destruction. Aggrecanases were more associated with the
increase of aggrecan loss associated with OA than MMP1
[51]. Thus, it can be concluded that MMPs are responsible
for the normal cell aggrecan turnover, while aggrecanases
contribute to its degradation under pathological conditions.
In another study, when aggrecanase was inhibited, aggrecan
levels gets increased, and the severity of OA gets decreased
in animal models but when aggrecanase was given exter-
nally, the result was the opposite, i.e., aggrecan level gets
decreased with increasing severity of OA [52]. It is indicating
that there is not one protease responsible for cartilage ero-
sion in OA but multiple proteases are responsible. Thus,
rather than targeting an individual protease for OA therapy,
directing research to control global protease generation may
be more productive.
Fibulin peptides (Fib-3-1, Fib-3-2) are seven members of
the mammalian fibulin family of glycoproteins and are asso-
ciated with cartilage ECM. Basement membrane components
such as proteoglycans, fibronectin, and fibrin have binding
sites for Fib3-1 and Fib3-2 [53]. Specific immunoassays were
developed to identify Fib3-1 and Fib3-2 in the serum and
cartilage of OA patients, and their levels were increased in
the serum of patients with severe knee OA compared to
age-matched healthy control and were reported to be poten-
tial biomarkers of OA [54]. In another study, it has been
found that increased levels of fibulin-3 epitopes are associ-
ated with middle-aged overweight, obese women, and
chronic pain but are not associated with knee JSN and
K&L scores [55]. Together, we can conclude that fibulin-3
epitopes make more clinical predictions than radiological
features in the OA population.
Follistatin-like protein 1 (FSTIL 1) is a secreted glycopro-
tein, plays an important role during cell differentiation and
proliferation, and is related to joint damage in OA. It is ele-
vated in the serum, synovial tissues and SF of OA patients
and is weakly expressed in the chondrocytes of the articular
cartilage superficial zone in OA. In a gender-based study, it
was found that level of FSTL1 was significantly higher in
female OA patients compared to male patients [56]. Other
studies reported that FSTL1 functions as a novel proinflam-
matory protein, inducing the production of cytokines TNF-
Table 2: List of biomarkers routinely used in the diagnosis and treatment of osteoarthritis and the studies of these markers in patients.
Biomarker name Description Evidence for role in OA Sample type Expression level in OA References
Coll-2 Type-II collagen Cartilage loss S, SF Upregulated [28]
PIIANP Type IIA collagen N-propeptide
Proanabolic agent of
cartilage
S, SF Downregulated [32]
CPII
Type II procollagen carboxy
propeptide
Destruction and loss of
cartilage
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S: serum; SF: synovial fluid; U: urine.
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α, IL-1β, IL-6, and IL-8, mediating proinflammatory events
in animal models. It activates several signaling pathways
including IFN-γ signaling, NF-Kβ pathway, p53, and p21
pathways [57]. An increase in the expression of FSTL1
induces arthritis and suppresses the production of
chemokine-10 (CXCL10) and interferon-gamma (IFN-γ) in
arthritic joints. FSTL1 is thus playing a crucial role in arthri-
tis by inducing the IFN-γ signaling pathway and stimulating
the molecular and cellular mechanism of innate and adaptive
immune responses [58]. Several studies also provided evi-
dence that FSTL1 can be utilized to check the severity of joint
damage and is reported to be a potential biomarker for the
monitoring of the progression of OA.
3.3. Inflammatory Biomarkers. Although the role of inflam-
mation in OA has been heavily debated, several studies and
evidence from MRI demonstrated that inflammation is also
a feature of synovial joints in OA. During inflammation,
macrophages and other immune cells get activated and mod-
ulate cytokine, metalloproteinase (MMPs), and complement
systems [59]. The inflammatory factors are cellular factors
(macrophages), molecular factors (cytokines and chemo-
kines), and complement components that are playing a role
as biomarkers and are responsible for the catabolic and ana-
bolic destruction of the synovial joints [60]. As a part of the
immune system and inflammation, the complement pathway
contributes to immune responses by enhancing the action of
antibodies and immune cells against antigens [61]. Activa-
tion of the complement pathways occurs due to tissue metab-
olism (cartilage and synovium), causing cartilage destruction
and synovial inflammation, and is especially correlated with
the radiographic severity of disease suggesting it as a marker
for OA [62]. In OA, the concentration of complement com-
ponents -C3, C5, and C9 and the complement effectors C7,
C4a, and factor B were significantly higher in the SF of early
OA. Factor H, C4–binding protein, C1 inhibitors, and clus-
terin are complement inhibitors expressed lower in OA
[63]. It is found that many cartilage degradation proteins
become high in the plasma and SF of OA due to activation
of the complement pathway [61].
Macrophage cells are the most important cells of synovial
tissues, producing aggrecanases, MMPs, and other destruc-
tive mediators such as IL-6 and TNF-α that are responsible
for inflammatory responses. The production of these proin-
flammatory products depends on the NF-κB signaling path-
way, TLR receptors, and pathogen recognition pattern
(PRR) receptors that are associated with tissue damage,
inflammation, and cartilage erosion [24]. Most of the cyto-
kines in OA joints are macrophage-mediated. Surface
markers CD14 and CD163 were highly measured in plasma,
serum, and SF in OA [64]. In OA, the expression of chitinase-
3-like protein 1 (YKL-40), a heparin-chitin binding glyco-
protein secreted from macrophage and chondrocyte during
inflammation, was increased in plasma of severe OA com-
pared to normal and mild OA [65]. Macrophages activate
an innate immune response in OA pathology and progres-
sion. Thus, the products of macrophages play a role in OA
pathology and can be used to understand OA mechanism
and therapeutic innovations [66].
Cytokines and chemokines are small proteins secreted by
immune and other cell types. Cytokines are of two types, pro-
inflammatory: interleukin-1β (IL-1β), IL-6, IL-7, IL-15, IL-
17, IL-18, TNF-α, or anti-inflammatory: IL-4, IL-8, and IL-
10 [67]. IL-1β is produced by chondrocytes, osteoblasts,
and synovial membrane, highly expressed in OA patients.
IL-1 increases the expression of MMPs and nitric oxide
(NO) expression, inhibits the synthesis of both proteoglycan
and collagen, and thus promotes inflammatory responses
[68]. The catabolic effect on synovium tissue is due to activa-
tion of Wnt target gene transcription by decreasing the
expression of dickkopf the WNT signaling pathway inhibitor
1 (DKK1) and secreted frizzled-related protein 3 precursor
(FRZB) [69]. Levels of proinflammatory cytokines IL-6 and
TNF-α were elevated in OASF. Expression levels of TNF-α
were highly increased in OA patients but soluble TNF-α
receptor levels were found to be lower in OASF and plasma
[70]. Increased levels of IL-6 and TNF-α are associated with
JSN that induces cartilage loss by activating NF-κB and
MAPK signaling pathways. Activated NF-κB upregulates
the expression of chemokines, cytokines, and many other
growth factors which lead to an imbalance in the homeostasis
of the subchondral bone [71]. The expression level of IL-6
can be induced by IL-1β in chondrocytes during inflamma-
tion that suppresses type-II collagen activity, leading to carti-
lage degeneration and an increase in the high level of IL-6 in
OASF [72]. IL-7 is a hematopoietic growth factor secreted by
the stromal cells, considered to be a proinflammatory factor,
highly expressed in OA synovium, and involved in regulating
bone homeostasis [73]. IL-4 and IL10 are anti-inflammatory
cytokines, and levels were found to be reduced in OA plasma,
suppressing bone resorption in OA. IL-4 inhibits the expres-
sion of IL-1, IL-6, MMP13, TNF-α, and receptor activator of
nuclear factor β ligand (RANKL) in the cells that modulate
osteoclast proliferation [74].
Other inflammatory markers and chemokines are small
molecular weight and cell signaling proteins that attract cells
via chemotaxis. These are secreted during the immune
response and regulate the migration of cells during the devel-
opment of immune response [75]. Chemokines such as
CCL14, CCL19, CCL20, CCL21, CXC27, and CXCL12 are
responsible for homeostasis while CXC8, CCL2, CCL3,
CCL5, and CXCL10 are partners in the inflammatory
response [76]. The levels of chemokines were high in the
plasma and SF of OA patients, causing cartilage loss and
inflammation in the synovial membrane [77]. Thus, inflam-
matorymediators are playing a role in OA progression by acti-
vating several signaling pathways, including the NF-κB
signaling pathway, the wnt signaling pathway, the TLR-4
receptor, and the MAPK signaling pathway [78]. They can
be used to understand mechanisms and pathways responsible
for OA progression and help in the discovery of new drugs by
targeting their specific receptors as shown in Figure 3.
3.4. Posttranslational Modifications (PTM) in Extracellular
Matrix Molecules. In cartilage, posttranslational modifica-
tions (PTMs) in proteins can enhance the proteome com-
plexity by altering the proteins involved in enzymatic,
biochemical, and physiological processes affecting OA
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pathogenesis. Therefore, identification and understanding of
PTMs are important in OA disease treatment and prevention
[79]. Posttranslational modifications can be grouped into
natural which include methionine, oxidation, phosphoryla-
tion, ubiquitination, deamidation, and synthetic subgroups.
Nonenzymatic PTMs such as the deamidated epitope of car-
tilage oligomeric matrix protein (D-COMP) and pentosidine
can be used to examine deficiencies in extracellular matrix
macromolecules in OA [80].
The deaminated epitope of COMP (Asn64 converted into
Asp64) is known as D-COMP. A comparative study between
D-COMP and total native COMP in the patients undergoing
joint replacement surgery has shown increased expression
levels of serum D-COMP as well as a decline D-COMP after
replacement of joint tissue in knee OA [80]. Expression levels
of D-COMP were found to be significantly higher in hip car-
tilage lesion extracts than in knee OA lesions. Hence, D-
COMP in cartilage and systemic circulation was reported to
be the first biomarker for specific joint tissue sites. In con-
trast, COMP was associated with radiographic knee OA but
not associated with hip OA severity [81]. Thus, the PTMs
in COMP may be related to the progression of OA in differ-
ent joints.
Pentosidine is a biomarker for advanced glycated end
products (AGEs), rapidly produced under various types of
oxidative stress and hyperglycemia in articular cartilage,
serum, urine, and SF [82]. Pentosidine levels were mostly
increased in inflammation conditions, associated with OA.
The expression level of urinary pentosidine levels was also
found to be elevated in patients with hand, knee, and hip
OA. Urinary pentosidine levels were related to the measure-
ments of joint pain, stiffness, and disability in patients with
erosive hand OA [83]. Urine pentosidine positively corre-
lated with both C-reactive protein (CRP) and erythrocyte
sedimentation rate (ESR) levels during oxidative stress. An
increased level of pentosidine was also found in disease con-
ditions associated with increased oxidative stress. Nonenzy-
matic glycation of proteins was also associated with aging,
increased cartilage stiffness, increased degradation of ECM
proteins, and decreased proteoglycans synthesis by chondro-
cytes [84]. The accumulation of pentosidine in cartilage was









Figure 3: Biomarkers play role in pathology of OA bymultiple signaling pathways including NF-κB pathway, MAPK pathway,Wnt-signaling
pathway, and TLR pathway. Wnt: wingless and Int-1; APC: adenomatous polyposis coli; GSK3β: glycogen synthese kinase; DSH:
phosphoprotein disheveled; IL-1β: interleukin 1 beta; GRB2: growth factor receptor-bound protein 2; MAPK: mitogen-activated protein
kinase; ERK: extracellular signal-regulated kinase; JNK: c-Jun N-terminal kinase; TLR4: toll-like receptor 4; MD88: myeloid differentiation
primary response 88; IKK: inhibitor of nuclear factor-κB (IκB) kinase; NF-κB: nuclear factor kappa light chain enhancer of activated B
cells; IRAK: IL-1 receptor-associated kinase; P: phosphorylation; UQ: ubiquitin; CREB: cAMP-responsive element binding protein; TCF: T
cell factor; TAK1: transforming growth factor b-activated kinase 1; MMP: matrix metallopeptidases; VCAM-1: vascular cell adhesion
protein; ICAM-1: intercellular adhesion molecule 1.
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progression of OA. In conclusion, high levels of pentosidine
in OA and RA patients indicate that this compound is not
only a marker of glycoxidation but may be used as a more
general marker of oxidative stress in different pathologies
inluding OA [85].
3.5. Other Biomarkers. Several aggrecanase enzymes (a disin-
tegrin and metalloproteinase with thrombospondin motifs
ADAMTS) and proteolytic enzymes such as metalloprotein-
ases (MMPs) and obesity-related proteins are associated with
cartilage degradation and are identified as OA biochemical
markers [86].
A disintegrin and metalloproteinase with thrombospon-
din motifs (ADAMTS), a family of secreted metalloprotein-
ase, involved in various developmental and homeostatic
processes. This ADAMTS degrades type II collagen and
aggrecan and is associated with the progression of OA [87].
The ADAMTS-1 expression was significantly upregulated
in OA cartilage but showed reduced expression in late-stage
OA. Immunohistochemistry analysis indicated that in the
normal cartilage, ADAMTS-1 was predominantly expressed
in the superficial zone, whereas the central zone and osteo-
phytes showed increasing levels of expression of ADAMTS
[88]. ADAMTS-2, 3, and 14 are procollagen N-proteinases
responsible for the removal of the N-terminal propeptide of
type I, II, III, and V procollagen and thereby the formation
of the collagen fibrils. The expression levels of ADAMTS-
2,-3, and -14 were found to be significantly upregulated in
the OA cartilage. Single nucleotide polymorphisms in the
ADAMTS-14 gene were reported to be associated with an
increased risk of knee OA in two female cohorts [89]. The
two “aggrecanases” ADAMTS-4 and -5 degrade the aggrecan
and collagen, and their degradation was correlated with the
progression of OA [90]. ADAMTS-7 and 12 were found to
contribute to OA pathogenesis by degrading COMP. The
degradation of COMP can be inhibited in vitro by adding
ADAMTS-7 neutralizing antibodies or small interfering
RNA (siRNA) [91]. ADAMTS-9 was expressed in normal
cartilage and was induced in response to proinflammatory
cytokines and adipokines and was found to be reduced in
late-stage OA cartilage [92]. ADAMTSs bind with cytokines,
growth factor precursors, and their cytoplasmic domain, acti-
vate intracellular signaling cascades, and stimulate secretions
of MMPs, IL-6, TNF-α, and other proinflammatory markers.
Therefore, ADMTS-4 and -5 and many other ADAMTs can
be used to understand the pathophysiology of OA and to
enable targeted inhibitors for cartilage repair [93].
Adipokines: the adipocyte-derivedmolecules “adipokines”
also play an important role in cartilage and bone homeostasis
in OA. The association of adipokines with obesity, having both
properties, pro- or anti-inflammatory properties, suggests that
adipokines are an important mediator that links inflammation
with obesity and OA [94]. Adipokines such as leptin, adipo-
nectin, visfatin, and resistin play an important role in OA
and are used as markers for OA. All of the three adipokines
(leptin, visfatin, and resistin) were elevated in OA plasma
while adiponectin was increased in OA SF [95]. Leptin induces
chondrocytes to secrete cartilage degradation mediators such
as TNF-α, IL-1β, IL-6, IL-8, reduced proliferation of chondro-
cytes, increased osteoblast proliferation, and ossification of
cartilage, increasing inflammation in OA [96]. Leptin stimu-
lates cytokine secretion and proliferation of T-cell through
theMAPK and phosphatidylinositol-3 kinase (PIK3) pathway.
It thus induces two different markers early activation marker
(CD69) and late activation marker (CD25 and CD71) in T
lymphocyte cell that leads to inflammation in synovial joints
[97]. Other adipokines such as adiponectin that has both cat-
abolic and anabolic effects provide a proinflammatory func-
tion by stimulating NOS2, MCP-1, MMP-1, MMP-3, MMP-
9, MMP-13, IL-6, IL-8, PGE2, and vascular endothelial growth
factor (VEGF) [98]. Adiponectin stimulates the release of anti-
inflammatory molecules (IL-10 and IL-1) receptor antago-
nists, suggesting a protective role against cartilage damage.
Besides, adiponectin has been shown to increase chondrocyte
proliferation, aggrecan synthesis, matrix mineralization, and
upregulated type II and type X collagen expression [99].
In order to understand the role of obesity in OA develop-
ment, an association of leptin and adiponectin with adiposity
and OA was evaluated and found that leptin was strongly
associated with knee OA compared to hand OA but adipo-
nectin was not associated with either knee and hand OA
[100]. In vitro and in vivo studies have shown that leptin
receptors are overexpressed in the cartilage and osteophytes
in OA providing further support that leptin signaling is
essential for obesity-induced OA development [101, 102].
The expression levels of visfatin and resistin were signifi-
cantly upregulated in erosion hand OA (E-HOA) compared
to normal controls (NC). The expression of the resistin was
also higher in nonerosive hand OA (NE-HOA) than in con-
trols, but the level of the visfatin was only higher in E-HOA.
So, these result showed that visfatin is a good biomarker to
distinguish the difference between E-HOA and NE-HOA.
Furthermore, the high level of resistin in serum suggests a
possible role in OA pathophysiology [103]. Another study
was performed to understand the effect of adipokines on
microRNAs (miRNA), MMPs, and collagen type II alpha 1
chains (Col2a1) in OA pathology. OA chondrocyte cells
were stimulated with visfatin and resistin at optimal concen-
tration. It was found that the expression levels of miRNA
(34a, 155, 181a, let7e), MMP1, and MMP13 were signifi-
cantly higher while miRNA-140 and Col2a1 were downreg-
ulated in the cartilage. Increased levels of miRNA play a role
in cartilage breakdown, cell differentiation and proliferation,
production of inflammatory cytokines, and cartilage homeo-
stasis [104].
Retinol binding protein (RBP-4) is an adipocyte-derived
factor and a member of the lipocalin family that plays a role
as a vitamin A carrier in the blood and is functionally
involved in insulin resistance (type 2 diabetes) and metabolic
syndrome (MetS). The expression level of RBP4 was found to
be significantly upregulated in plasma, SF, cartilage tissue,
and chondrocytes of OA. In cartilage tissue of OA, RBP4 is
positively associated with other adipokines (adipsin, leptin,
and resistin), metalloproteases (MMP1 and MMP3), and
proinflammatory protein YKL-40. RBP4 induces the expres-
sion of inflammatory and catabolic factors in OA disease by
activating stimulated by retinoic acid gene homolog 6′
(STRA6) receptor and TLR-4 signaling pathway [105]. But
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out of them, no individual adipokine has been reported to be
used in the diagnosis of OA. In conclusion, it can be said that
adipokines play an important role in OA progression and
pathology. For the treatment of OA, specific adipokines
may be useful to develop a therapeutic molecule that targets
specific adipokines [106].
4. Omic Approaches for
Identification of Biomarkers
Different techniques and methods of proteomics approaches
are used for the identification of proteins, their activity, and
presence as biomarkers in disease conditions compared to
control from different samples [107]. For the discovery of
new biomarkers, these approaches include some essential
steps as shown in Figure 1: extraction and separation of pro-
teins, identification of proteins, and validation of proteins.
Finally, the discovery of a new biomarker requires clinical tri-
als [108].
Proteins are extracted and separated by two-dimension
gel electrophoresis (2-DE), and proteins are separated based
on isoelectric points and molecular weights for the ability
to compare the number of proteins and isoforms in the same
gels [109]. Two-dimensional intergel electrophoresis (2D-
DIGE) is also used to extract and separate proteins and is
more reliable than 2-DE because it provides greater sensitiv-
ity and reproducibility. In this method, different types of
fluorescent dyes are used for the labeling of proteins, and
these signals can also be used to identify proteins at the same
spots in the gel [110]. There are different proteomics tech-
niques used for the identification of proteins including
matrix-assisted laser desorption/ionization time-of-flight
(MALDI-TOF), liquid chromatography with tandem mass
spectroscope (LC-MS/MS), surface-enhanced laser deso-
rption/ionization-time-of-flight (SELDI-TOF), selected reac-
tion monitoring (SRM), and multiple reaction monitoring
(MRM) [111, 112].
High-throughput quantitative techniques like proteo-
mics analysis have also been utilized for the discovery of
lower abundance ECM components, lipoproteins, and com-
plement components in OA serum and SF to identify novel
diseases relevant to OA biomarkers. The MALDI-TOF and
LC-MS/MS are used to determine the differentially expressed
proteins in OA [113]. Many proteins have been identified in
the different biological fluids such as blood, urine, SF, and tis-
sue [114]. Besides, ingel digestion and reverse-phase peptide
separation were used in the liquid chromatography system.
The majority of the proteins identified are involved in
inflammation (COMP), complement activation (C3-C4),
and immune responses (MMP) [114]. It can therefore be con-
cluded that proteomics analysis followed by MALDI and
imaging mass spectroscopy (IMS) is used to identify differen-
tially expressed proteins to specific anatomic areas of joint tis-
sues of OA patients and is a powerful technique to examine
the photomicrograph of the selection before the usage of
MALDI [115]. In a comparative study of protein patterns
from OA and non-OA, cartilage tissues were digested with
metalloproteases enzyme, released breakdown products of
cartilage tissue, type II collagen, fibronectin, COMP, and
aggrecan and were monitored by LC-MS/MS [116].
The SELDI-TOF technique was used to analyze SF sam-
ples from OA patients, a chromatographic surface that can
bind with the specific site of interested protein based on elec-
trostatic interaction, absorption, and biochemical affinity.
The result demonstrated that three mass peaks were identi-
fied as potential markers (3893, 10576, and 14175Da), to
differentiate OA. Out of them, the peak 10576Da was iden-
tified as S100 calcium-binding protein with a sensitivity of
89.4% and specificity of 91.2% [117]. Selected reaction mon-
itoring (SRM) and multiple reaction monitoring (MRM)
were used to validate differentially expressed proteins such
as the dickkopf WNT signaling pathway inhibitor 3
(DKK3) in the SFof control and OA [118]. Several proteo-
mic techniques are available for the validation of these iden-
tified proteins, including western blotting and enzyme-
linked immunosorbent assay (ELISA). Expression of these
biomarkers including collagen breakdown products (type II
collagen, PIIANP, and CPII), noncollagenous proteins
(COMP, aggrecan, fibulin 3-1, and FSTL-1), and inflamma-
tory biomarkers (IL-1β, TNF-α, and cytokines) was moni-
tored by western blotting and ELISA in the different
biological fluid (serum, urine, synovial fluid, and tissue) of
OA and control [40, 46, 54, 60]. To understand the role of
these biomarkers in OA pathophysiology, bioinformatic
tools are used to monitor physiological connection and their
interactions with other proteins [119]. Bioinformatic tools
such as GO annotation, DAVID, KEGG pathway, and
STRING analysis were used to analyze omics data, function
analysis, pathway analysis, protein-protein interactions, and
interpretation of data [120].
Other omic-based approaches such as genomics and
metabolomics approaches are used to understand disease
mechanisms and identify biomarkers for the discovery of
therapeutic and clinical development. [121]. The genomic
approaches were used to identify genetic mutations (whole
genome), genetic variations with disease condition using
genome-wide association studies (GWAS), identification of
differentially expressed genes (DEGs) by gene expression
omnibus (GEO), and m-RNA and mi-RNA expression by
microarray to compare between control and disease condi-
tions [122–124]. The identified gene (COMP gene) was used
for disease diagnosis, prognosis, and therapeutic efficiency
[41]. The metabolomic approach has the ability to detect
metabolites from biological fluids using nuclear magnetic
resonance (NMR) and mass spectroscope (MS) that detect
biomarkers for early-stage diagnosis of OA [125]. The
expression level of arginine metabolites was found to be
decreased in the plasma of OA patients, leading to an imbal-
ance between cartilage erosion and repair [126]. Other
metabolites such as taurine and L-carnitine has been
reported to be involved in the pathogenesis of subchondral
sclerosis [127]. Metabolic arrays are used to detect early-
stage biomarkers and their identity to monitor changes in
disease status [125]. Thus, these proteomic approaches are
promising approaches for identifying reliable biomarkers,
can be used to diagnose disease, monitor disease progression,
and discover new therapeutic drugs.
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5. Conclusion
As seen from the presented literature, there are many chal-
lenges in interpreting the results of biomarker studies. How-
ever, the main limitation is the specificity of the biomarker
for a particular outcome in OA, particularly as there is a pau-
city of reference measures usable in OA and notably sensitive
to change. The biomarker must be highly specific and sensi-
tive to OA joints that can be used for diagnosis, prognosis,
and treatment of OA. Currently, joint pain, stiffness, and
joint deformity that are the hallmarks of OA initiation are
monitored by radiographic analysis. Special diagnostic tools
and treatments for OA rarely exist; so, this problem could
be resolved by identifying some reliable biomarkers that
can be widely implemented in clinical settings. In the case
of OA disease, tissues undergo metabolic changes as well as
structural and morphological changes. Several biomarkers
related to metabolic changes can provide valuable informa-
tion for the diagnosis and development of new drugs for
the treatment of OA. This review demonstrates that the
imbalance of degradation and synthesis of cartilage disrupts
by multiple factors, including aging and mechanical loading
on the joints. Beside this, the involvement of different signal-
ing pathways can disrupt the balance between catabolic and
anabolic activities in cartilage that results in degradation of
proteoglycan and ECM component. Manipulation of the
abovementioned molecules in particular chondrocytes could
also play a role in articular cartilage regeneration. Further,
studies will explore these biomarkers with clinical settings,
be used for the diagnosis of OA at an early stage, and help
in the treatment of OA cost-effectively by discovering new
therapeutic drugs. Beyond the aspects, there is a need for
awareness of a different kind of molecular mechanisms
involved in OA onset and progress, which could stimulate
understanding about early diagnosis and therapeutic inter-
vention. Novel proteomic techniques and approaches as well
as new application are needed to accomplish the identifica-
tion of specific protein as a biomarker for diagnosis and treat-
ment of OA. As a final remark, novel diagnostic markers are
urgently needed to improve the prognosis of OA patients.
Additional Points
Highlights. (1) OA is a cartilage degenerative disease with an
unknown molecular mechanism. (2) Biomarkers can be used
for OA diagnosis and therapeutic drug discovery. (3) Most of
the biomarker are the result of metabolic changes of tissue
such as cartilage, bone, and synovium metabolism.
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